ReviewArchives of toxicology2025
Exploring the multifaceted impact of bisphosphonates on bone graft integration: transitioning from in vivo insights to clinical applications.
Review in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Numerous researchers have explored the efficacy of the use of bisphosphonates, in particular alendronate and zoledronate, in bone graft integration. Mechanisms underlying the beneficial effects of bisphosphonates on bone graft integration have been previously investigated. Previous studies have demonstrated that both local and systemic applications of bisphosphonates in the integration of autogenous and allogenic bone grafts yield promising results in enhancing allograft and autograft outcomes. Several animal studies have revealed that low to moderate doses of local bisphosphonate optimize new bone formation with good mechanical properties. In addition, bisphosphonates in combination with certain growth factors, such as bone morphogenetic protein (BMP)-7, have synergistic effects on the integration of both autogenous and allogenic bone grafts. However, only some clinical parameters support these findings from in vivo studies, including increased bone volume and density in bone-grafted areas following the integration of bone grafts. Thus, the present review aims to summarize and discuss the effects of bisphosphonates and the mechanistic insights associated with the integration of autogenous and allogenic bone grafts. The contradictory findings between studies will also be presented and discussed in this review. While the promising benefits of bisphosphonates on bone grafts have been reported, further research is still needed to investigate optimal dosage. Larger clinical trials to assess the long-term outcomes of bisphosphonates are required before they can be widely adopted in orthopedic, dental, and maxillofacial bone grafting procedures.
Indexed as
Identifiers
40047864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.